Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib and 5-Fluorouracil in Advanced Colorectal Cancer
NCT03210064Phase 2Unknown
- Sponsor
- Hui-Ting Xu
- Start
- May 2017
- Primary completion
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of Rivoceranib in colorectal cancer (metastatic) (mCRC), sponsored by Hui-Ting Xu. Status: unknown.
02
Drugs
Rivoceranib
03
Conditions
colorectal cancer (metastatic) (mCRC)
Beyond the preview
Go deeper on NCT03210064.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03210064.